Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer.
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer.
复制标题
MeCP2在泛癌中的预后价值和免疫学作用的生物信息学分析
DOI：
10.1038/s41598-022-21328-8
复制
发表时间：
2022-11-02
影响因子：
4.6
通讯作者：
中科院分区：
文献类型：
--
作者：
甲基CpG结合蛋白2（MeCP2）是一种重要的表观遗传调控因子，可促进多种肿瘤的发生，如肝癌、乳腺癌和结直肠癌。迄今为止，尚未有泛癌分析的报道。因此，本研究旨在探讨泛癌的预后价值、免疫浸润模式和生物学功能。我们利用公共数据库，利用生物信息学方法分析了MeCP2的表达和预后意义，以及MeCP2与泛癌临床病理参数、遗传变异、甲基化、磷酸化、免疫细胞浸润和生物学功能的关系。结果显示，MeCP2在8种癌症中表达上调，在2种癌症中表达下调，与癌症的预后、病理分期、分级和亚型显着相关。膀胱尿路上皮癌（BLCA）、乳腺浸润性癌（BRCA）、肝细胞癌（LIHC）、前列腺腺癌（PRAD）、子宫体子宫内膜癌（UCEC）、睾丸生殖细胞肿瘤（TGCT）和胃腺癌（STAD）中MeCP2 DNA启动子甲基化水平降低；S25、S90、S92、 S241、S286、S325和S435存在于MeCP2中，例如UCEC、肺腺癌(LUAD)、卵巢浆液性囊腺癌(OV)、结肠腺癌(COAD)和肾肾透明细胞癌(KIRC)。此外，MeCP2 表达与大多数肿瘤中的多种免疫调节剂和免疫细胞浸润水平显着相关。因此，我们的泛癌探索了MeCP2在不同癌症中的预后标志物和免疫治疗价值。
Methyl-CpG-binding protein 2(MeCP2) is an important epigenetic regulatory factor that promotes many tumor developments, such as liver cancer, breast cancer, and colorectal cancer. So far, no pan-cancer analysis has been reported. Therefore, this study aims to explore pan-cancer's prognostic value, immune infiltration pattern, and biological function. We used bioinformatics methods to analyze the expression and prognostic significance of MeCP2, and the relationship between MeCP2 and clinicopathological parameters, genetic variation, methylation, phosphorylation, immune cell infiltration, and biological function in pan-cancer from using a public database. The results showed that expression of MeCP2 was up-regulated in 8 cancers and down-regulated in 2 cancers, which was remarkably correlated with the prognosis, pathological stage, grade and subtype of cancers. The promoter methylation level of MeCP2 DNA was decreased in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), liver hepatocellular carcinoma (LIHC), prostate adenocarcinoma (PRAD), uterine corpus endometrial carcinoma (UCEC), testicular germ cell tumors (TGCT), and stomach adenocarcinoma (STAD);decreased phosphorylation of S25, S90, S92, S241, S286, S325 and S435 was found in MeCP2, such as UCEC, lung adenocarcinoma (LUAD), ovarian serous cystadenocarcinoma (OV), colon adenocarcinoma (COAD), and kidney renal clear cell carcinoma (KIRC). Furthermore, MeCP2 expression was significantly associated with multiple immunomodulators and immune cell infiltration levels across most tumors. Therefore, our pan-cancer explored the prognostic markers and immunotherapeutic value of MeCP2 in different cancers.
登录
查看更多内容
PD-1和PD-L1抑制剂作为癌症免疫疗法的一种形式的开发：对注册试验和未来考虑的全面综述。
影响因子：
10.9
作者：
Gong J;Chehrazi-Raffle A;Reddi S;Salgia R
通讯作者：
Salgia R
甲基CpG结合蛋白2基因的表观遗传沉默影响人骨肉瘤细胞的增殖、侵袭、迁移和凋亡
影响因子：
--
作者：
Meng, Gang;Lv, YangFan;Guo, Qiao-Nan
通讯作者：
Guo, Qiao-Nan
肝细胞癌中关键生物标志物的筛查和鉴定：来自生物信息学分析的证据。
影响因子：
4.2
作者：
Li L;Lei Q;Zhang S;Kong L;Qin B
通讯作者：
Qin B
影响因子：
5.2
作者：
Lin, Ching-Yu;Wang, Bi-Juan;Chuu, Chih-Pin
通讯作者：
Chuu, Chih-Pin
影响因子：
5.3
作者：
Liu JN;Kong XS;Sun P;Wang R;Li W;Chen QF
通讯作者：
Chen QF